Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Quick to assume failure. This is drug development not some supermarket where you pick things from the shelf. Trial and testing and timings are often over exaggerated.
Still very much open could go either way but at this market cap only one success is needed for a multi bagger.
I would think SAR is almost certain to be delisted given how low the market cap vs actual spend and requirements for cash.
Valirx has potential with a very modest cash burn. It takes time to find top quality compounds which they have done and now just a bit of work before it is ready for a deal at the preclinical stage. We just need one. CLX is our best hope with the Imperial compound.
The fact the merger work is still ongoing since October then that means it is highly likely to be successful as you don't fail after 6 months of work. If that completes it likely means a much higher market cap and more cash and any rise will be very significant in the medium term.
Cash runway now appears sufficient to carry it well into 2025
Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the
acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for
the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during
which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank
materials in tandem with commercial development/brand establishment within Inaphaea while also advancing
its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway
sufficient to carry it into Q2 2025.
Between now and then, of course, various upside scenarios suggest this period could become significantly extended.
This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential
signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing
development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing
milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also
proving its business model.
1) You are wrong because I am in no doubt that this Adrian person would help put some incentives for board members with decent targets by June.
2) He was backed by the private shareholder group and others so if he goes in and does a placing at such a crazy price then he has already failed and should be removed immediately as he has no experience in this field and if he goes against what existing shareholders want then it will be curtains for him. I see no reason why the cash burn should increase beyond what has been projected.
The BOD members have not been confirmed yet but I doubt they will be rewarded with very high salaries or that we see more people on the BOD than before.
The projection remains at the end of Q1 2025 and that without any revenue.
Show us the money Porky. Show us the money.
SInce 4D went down I have not seen you ramp a single stock something you would do often in various stocks before 4D day and night. My guess is you simply have nothing left to invest. I find it hard to believe you do not find one stock that is worth posting positively about since 4D collapsed.
Your stock analysis is biased. They have done a great job bringing in top quality projects and having a lab to support it. 201 has been handled poorly but It can still complete soon and hopefully the company will get stronger and stronger after that completes. Not many AIM companies do so much and yet spend only 2 million a year, looking at 4D burning 55 million a year with zero revenue but that was investible to you who was posting his buys on Twitter.
If 201 happens then this should be a 20 bagger in the next 12-18 months when the market improves and hopefully with 1 good preclinical deal and given the quality of the new compounds that is likely.
Calling a 1p placing or no support at all and at 6p which was mainly due to a leak is the same as calling a 30p placing at 6p. Then moving from July to August to September to October to November to December.
What idiot would think that is an accurate prediction.
Borgie,
Looks like you got smashed on BRH and all the other stocks so trying to crossramp here does not work given your track record.
Pure desperation to ask an elderly person to invest in your junk. What a joke.
I was about to post the same. After all these years he is still here with no investment.
No shareholder is going to listen to what you have to say unless you invest first. You have been moving from one thing to another for around 3 years. Very strange indeed to waste time on something he regards as having no value.
So you want 10 evaluations at £100 k a pot then after BOD salary leaves you with zero money to pay for lab staff or to invest in CLX. If there is no lab then you need to pay to outsource the compounds which cost more.
Your finance calculations are as bad as it was when you invested in 4D.
Constantly changing BOD is not going to change the outcomes. The outcomes need to be achieved. Changes only slows things down but then again you are not invested.
My reason for investing in Valirx is purely because of the low risk strategy. No clinical trials and looking for an early deal that would offer significant upfront payment and milestones.
If the strategy changed in the future I would be out. I don't believe that funding clinical trials on AIM would result in a return in investment in most cases especially in a bearish market.
Bit stupid to make a like for like comparison. They will probably list on Nasdaq so they have access to greater funds to fund the many 10s of millions they require to fund late stage trials which is very hard to raise on the AIM.
Valirx is not at that stage yet and also not full of institutional investors.
It does mean less competition and hopefully less choice. If outcomes are positive Valirx could move big.
The hope is that 201 will get signed before the next placing or we get some positive CLX news/deal, Lab contracts positive evaluation outcomes that increase the valuation .
Likely 15/20 million market cap if 201 signed. All depends and all relative to results/outcomes. At the moment nothing really is priced in.
DId I say 201 phase 2 trials were completed? If you are so worried about the peer review maybe look at Astrazeneca.
I invested based on the potential to get the compounds moving making it far more valuable and hopefully with a few deals. Not based on the finished product.
We are a better investment than any other biotech because raising 20/30/40 million in this market for clinical trials probably means a delisting. The lack of risk vs reward should see Val being one of the few that actually does very well. A 2 million cash burn is next to nothing compared to others to be fair as long as they can show some value.
We are not at that stage of peer reviews. We don't do clinical trials and have not completed a preclinical project yet. Nothing to conclude but potential is strong based on what is out in the public.
https://www.valirx.com/cytolytix-limited
https://www.dundee.ac.uk/stories/new-method-discovered-halt-active-cancer-cells
Compound from Imperial needs no introduction as to how good that would be.
Other than 201, we are investing in the hope that one of these compounds can get a large preclinical deal. Clearly all these show enough promise to indicate they will get through the early stages.
Well changes have been made. I never stated everyone should be removed but would have been in favour of a change with a shareholder on the BOD. I just don't see how widespread changes can make anything better or make it faster. It slows it down as we can all see now.
All that matters is outcomes. Even though I am significantly down I think that is more down to a lack of commercial skills on the BOD but I guess that is the reason why the action group picked Adrian otherwise why bother because he has no real experience in this work. The science work and control of finances has actually been really good and the foundations are strong.